Eri Kato

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6K citations · Full text

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn et al. · The Lancet Diabetes & Endocrinology · 2019 · 656 citations · Full text

Metabolic Syndrome, Declare–timi 58, Diabetes Management +10

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Eri Kato, Michael G. Silverman, Ofri Mosenzon et al. · Circulation · 2019 · 550 citations

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

Eri Kato, Robert P. Giugliano, Christian T. Ruff et al. · Journal of the American Heart Association · 2016 · 275 citations · Full text

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · American Heart Journal · 2018 · 179 citations

Metabolic Syndrome, Hypertension, Cardiovascular Disease +8